BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30710655)

  • 1. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
    Farah D; Leme GM; Eliaschewitz FG; Fonseca MCM
    Diabetes Res Clin Pract; 2019 Mar; 149():47-63. PubMed ID: 30710655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N; Muratov S; Levine M
    Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
    Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Doni K; Bühn S; Weise A; Mann NK; Hess S; Sönnichsen A; Pieper D; Thürmann P; Mathes T
    Ther Adv Drug Saf; 2022; 13():20420986211072383. PubMed ID: 35111291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH; Yin H; Azoulay L
    Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
    Yang M; Wang L; Gu L; Yuan W
    J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
    Gillani SW; Moosvi AF
    Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M; Shibasaki M; Echizen H; Kushiyama A
    PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
    Volke V; Katus U; Johannson A; Toompere K; Heinla K; Rünkorg K; Uusküla A
    BMC Endocr Disord; 2022 Oct; 22(1):251. PubMed ID: 36261824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?
    Ahrén B
    Curr Diab Rep; 2011 Apr; 11(2):83-90. PubMed ID: 21243448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Geng J; Yu H; Mao Y; Zhang P; Chen Y
    Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Tanenberg RJ
    Diabetes Res Clin Pract; 2015 Aug; 109(2):378-88. PubMed ID: 26059071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.